Q-omics provides the consensus-scored MIR22HG profile across patient tissues and cancer cell-line models. MIR22HG expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MIR22HG is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, MIR22HG RNA expression shows 21,680 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, KIRC, and GBM as cancer lineages where MIR22HG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR22HG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR22HG survival associations across molecular data types. MIR22HG RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR22HG RNA expression–survival associations across cancer types. High MIR22HG expression shows unfavorable associations in UVM, LGG, LUSC, THYM, GBM and KIRP. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MIR22HG RNA expression.
This table summarizes MIR22HG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR22HG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR22HG shows lower tumor expression in KIRC, THCA, BLCA, COAD, KIRP and LUAD. The KIRC box plot shows higher MIR22HG RNA expression in normal versus tumor tissue (log2 FC = −1.220, t-test p < 0.001).
This table shows molecular features associated with MIR22HG in patient tissues and cancer cell lines. In patient samples, MIR22HG shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
